MARKET

GLYC

GLYC

GlycoMimetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.365
-0.055
-1.61%
Opening 14:31 02/26 EST
OPEN
3.410
PREV CLOSE
3.420
HIGH
3.470
LOW
3.270
VOLUME
557.09K
TURNOVER
--
52 WEEK HIGH
5.19
52 WEEK LOW
1.820
MARKET CAP
160.94M
P/E (TTM)
-2.9895
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
How Much Of GlycoMimetics, Inc. (NASDAQ:GLYC) Do Institutions Own?
A look at the shareholders of GlycoMimetics, Inc. ( NASDAQ:GLYC ) can tell us which group is most powerful...
Simply Wall St. · 2d ago
8-K: GLYCOMIMETICS INC
(EDGAR Online via COMTEX) -- 0001253689false00012536892021-02-192021-02-1900012536892020-10-072020-10-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 2d ago
GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report fourth quarter and year-end 2020 financial results on Tuesday, March 2, 2021, at 8:30 a.m. ET.
BusinessWire · 2d ago
GlycoMimetics picks internal candidate for chief medical officer
GlycoMimetics ([[GLYC]] -10.0%) promoted Eric Feldman, M.D., to SVP and Chief Medical Officer; Dr. Feldman joined the company in 2019 and was earlier VP, Global Clinical Development."Eric is internationally recognized for his work
Seekingalpha · 3d ago
GlycoMimetics Names Dr. Eric Feldman As Chief Medical Officer
GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer GlycoMimetics, Inc. (NASDAQ:GLYC) today announced the promotion of Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer. Dr. Feldman
Benzinga · 3d ago
GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer
GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer
Dow Jones · 3d ago
C-X-C Chemokine Receptor Type 4 Market Growth Factors, Applications, Regional Analysis, Key Players and Forecasts2020-2027 By Ameco Research
pune, India, Mon, 22 Feb 2021 06:08:12 / Comserve Inc. / -- C-X-C Chemokine Receptor Type 4 market is segmented by Type, and by Application. Players,...
Comserve · 4d ago
Chemotherapy Induced Neutropenia Drug Market Size Research Report 2021 by Growth Drivers, Market Challenges, Restraints, Price and Forecast to 2027 Says Absolute Reports
Feb 19, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “Chemotherapy Induced Neutropenia Drug...
The Express Wire · 02/19 06:08
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GLYC. Analyze the recent business situations of GlycoMimetics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GLYC stock price target is 10.50 with a high estimate of 15.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 161
Institutional Holdings: 53.48M
% Owned: 111.82%
Shares Outstanding: 47.83M
TypeInstitutionsShares
Increased
30
5.93M
New
32
-5.63M
Decreased
22
1.28M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.69%
Pharmaceuticals & Medical Research
-0.97%
Key Executives
Chairman/Independent Director
Timothy Pearson
President/Chief Executive Officer/Co-Founder/Director
Rachel King
Co-Founder/Senior Vice President/Chief Scientific Officer
John Magnani
Chief Financial Officer
Brian Hahn
Senior Vice President
Eric Feldman
Senior Vice President
Armand Girard
Senior Vice President
Helen Thackray
Independent Director
Patricia Andrews
Independent Director
Mark Goldberg
Independent Director
Scott Jackson
Independent Director
Daniel Junius
Independent Director
Scott Koenig
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About GLYC
GlycoMimetics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. Its drug candidates include Uproleselan, GMI-1687, GMI-1359, Galectin Antagonists and Rivipansel. Uproleselan is a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia and a hematologic cancer. As a life-cycle extension to uproleselan, it has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is designed to inhibit both E-selectin and CXCR4. The Galectin-3 is a carbohydrate-binding protein. Rivipansel is a glycomimetic drug that acts as a pan-selectin antagonist that binds to all three members of the selectin family, E-, P- and L-selectin, for the treatment of vaso-occlusive crisis.

Webull offers kinds of GlycoMimetics Inc stock information, including NASDAQ:GLYC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLYC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLYC stock methods without spending real money on the virtual paper trading platform.